GlassScriptPhysician profile
Kelly Jones
NPI 1639199870
$2,406.68
in general payments reported to CMS, 2019-2025
19 companies · $363 in 2025
The $363 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $370 · 2020: $336 · 2021: $288 · 2022: $514 · 2023: $237 · 2024: $299 · 2025: $363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $899.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $898.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $877.20 | 2020-2023 | Invega Sustenna |
| Novo Nordisk INC | $226.67 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Alkermes, INC. | $160.87 | 2019 | |
| Merck Sharp & Dohme LLC | $146.63 | 2019-2025 | M-M-R II, Capvaxive, Gardasil 9 |
| Otsuka America Pharmaceutical, INC. | $138.54 | 2022-2024 | Rexulti |
| Lilly USA, LLC | $125.45 | 2024-2025 | Zepbound, Mounjaro |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $116.45 | 2023-2024 | Rexulti |
| Bausch Health US, LLC | $106.68 | 2019-2020 | |
| Indivior INC. | $93.35 | 2020 | |
| Allergan, INC. | $91.89 | 2019-2020 | |
| Hologic Sales and Service, LLC | $80.73 | 2021-2025 | Aptima, Thinprep 2000 Processor |
| Glaxosmithkline, LLC. | $54.10 | 2023 | Bexsero, Pediarix, Shingrix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $47.80 | 2022 | |
| Viiv Healthcare Company | $33.02 | 2024 | Cabenuva |
| Sunovion Pharmaceuticals INC. | $32.49 | 2020-2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $20.52 | 2022 | |
| Supernus Pharmaceuticals, INC. | $19.72 | 2025 | |
| Gilead Sciences, INC. | $17.98 | 2023 | Epclusa |
| Dynavax Technologies Corporation | $16.59 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.